[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360046-105":59,"doc-detail-360046-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-evolving-global-landscape-of-first-in-class-oncology-drug-innovation-review-article-open","The evolving global landscape of first-in-class oncology drug innovation - Review article - Open","","First-in-class (FIC) oncology drugs are defined by novel mechanisms of action or by targeting molecular entities previously not addressed. This review maps global FIC oncology approvals from 2009 to 2024 and examines how approved FIC therapies and potential FIC (PFIC) candidates in clinical development have evolved. An analytic framework with four FIC archetypes—new targets, new mutation subtypes, new modalities, and new multi-target strategies—clarifies translational paths, bottlenecks, and shifting drivers. Target novelty dominates many approvals, while PFIC candidates increasingly leverage technological advances in modalities such as cell and gene therapies, antibody-drug conjugates, proteolysis-targeting chimeras, cancer vaccines, and bispecific antibodies, expanding druggability while persistent challenges constrain real-world impact.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-evolving-global-landscape-of-first-in-class-oncology-drug-innovation-review-article-open/360046/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-evolving-global-landscape-of-first-in-class-oncology-drug-innovation-review-article-open/360046.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the review define first-in-class (FIC) oncology drugs?","Question",{"text":112,"@type":113},"FIC oncology drugs are defined as the first globally approved products featuring either novel molecular targets or novel mechanisms of action.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What time window and scope does the review cover for FIC oncology drug approvals?",{"text":117,"@type":113},"The review analyzes global FIC oncology drug approvals from 2009 to 2024 and considers both approved FIC therapies and potential FIC (PFIC) candidates in clinical development.",{"name":119,"@type":110,"acceptedAnswer":120},"What four archetypes are used to structure the analysis of FIC development?",{"text":121,"@type":113},"The framework includes new targets, new mutation subtypes, new modalities, and new multi-target strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360046,1790420277,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nREVIEW ARTICLE  \nOPEN  \nThe evolving global landscape of ﬁrst-in-class oncology drug innovation  \nXiangyun Mao 1,2, Zhaoqing Wang 1,2, Shu Kong3, Yue Yang4,5, Nancy A. Dreyer 6, Yi Ba 7, Michael T. Lotze8, Qimin Zhan 9,10 ✉ and Guanqiao Li 1,2 ✉  \n\n|  | First-in-class (FIC) oncology drugs—deﬁned by their novel mechanisms of action or targeting of previously unaddressed molecular targets—have emerged as a leading force in cancer therapeutic innovation. In this Review, we delineate the global landscape of FIC oncology drug approvals between 2009 and 2024 and analyze the evolving characteristics of both approved FIC therapies and potential FIC (PFIC) candidates in clinical development. To clarify the underlying dynamics of this evolution, we construct an analytic framework encompassing four distinct archetypes of FIC development: new targets, new mutation subtypes, new modalities, and new multi-target strategies. This typology enables a systematic dissection of divergent translational trajectories and bottlenecks across the evolving FIC landscape. While most approved FIC drugs are driven by target novelty, PFIC candidates increasingly capitalize on technological breakthroughs, particularly in modalities such as cell and gene therapies, antibody–drug conjugates, proteolysis-targeting chimeras, cancer vaccines and bispeciﬁc antibodies. These advances not only expand the boundaries of druggability but also redeﬁne how therapeutic interventions are conceived, delivered and translated into patient outcomes. Despite this momentum, critical bottlenecks—including the identiﬁcation and validation of tractable targets, high clinical attrition rates, and persistent disparities in global access—continue to limit the real-world impact of oncology innovation. Looking forward, the convergence of artiﬁcial intelligence, next-generation modalities, and translational collaboration may serve as powerful engines for translating scientiﬁc breakthroughs into widely accessible therapies and for driving sustainable, mechanism- |  |  |\n| --- | --- | --- | --- |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n| based innovations in oncology. |  |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:174 | ; [https://doi.org/10.1038/s41392-026-02606-7](https://doi.org/10.1038/s41392-026-02606-7) |  |\n|  |  |  |  |\n\nINTRODUCTION  \nOwing to its devastating nature and substantial global disease burden, cancer remains a central priority in pharmaceutical research and development (R&D) . In recent years, oncology has consistently led all therapeutic areas in terms of the number of newly approved drugs.1–3 A remarkable proportion of these approvals are ﬁrst-in-class (FIC) medicines—deﬁned as the ﬁrst globally approved products with either novel molecular targets or mechanisms of action (MoA) .4 These trailblazing drugs offer therapeutic opportunities for diseases with previously unmet medical needs and serve as powerful catalysts for continued biomedical innovation. By engaging previously unexplored biological circuits, FIC therapies have not only deepened insights into cancer pathogenesis but also inspired new paradigms in therapeutic development. Such breakthroughs are the products of decades of global scientiﬁc endeavors—rooted in the relentless pursuit of novel pathogenic mechanisms and empowered by transformative technological advances. This path has been far from linear and is marked by iterative cycles of hypothesis, failure, and reﬁnement.5,6 Nonlinear progression has fundamentally transformed the architecture of cancer care,  \nanchoring a shift toward mechanism-based, modular intervention strategies.  \nThe history of cancer therapy is deﬁned","cbCaiqqVRnuyf7Lw","https://ap.wps.com/l/cbCaiqqVRnuyf7Lw","pdf",3463613,25,"English","# Introduction\n## Innovation waves and the rise of first-in-class therapies\n## Definitions and therapeutic significance\n# Review scope and analytic framework\n## Four archetypes of FIC development\n## Drivers shifting from target novelty to advanced modalities","[{\"question\":\"How does the review define first-in-class (FIC) oncology drugs?\",\"answer\":\"FIC oncology drugs are defined as the first globally approved products featuring either novel molecular targets or novel mechanisms of action.\"},{\"question\":\"What time window and scope does the review cover for FIC oncology drug approvals?\",\"answer\":\"The review analyzes global FIC oncology drug approvals from 2009 to 2024 and considers both approved FIC therapies and potential FIC (PFIC) candidates in clinical development.\"},{\"question\":\"What four archetypes are used to structure the analysis of FIC development?\",\"answer\":\"The framework includes new targets, new mutation subtypes, new modalities, and new multi-target strategies.\"}]","The evolving global landscape of first-in-class oncology drug innovation - Review article - Open | PDF",1790138586,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9295fe70195da94a1fc73aa5dc596682.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c37e4b6653f17668028ba4473c4920d8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/266f36fc92388f77cbcd013c582936a9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/342eae7f45a9c132e9abe797001e74b9.webp",980,1301]